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could demonstrate in TEN-HMS. We had no learning period to
identify appropriate triggers and responses to the new information
being acquired. The analyses they request are only now being done;
the techniques required are complex to apply. We also agree that
remote telemonitoring by people who have little knowledge of the
patient and who are not in a position to offer practical help if
needed is unlikely to be optimal. Telemedicine that integrates care
at the local and regional level is most likely to meet with success.
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Pleiotropic Effects of Statins and Early
Benefit in the PROVE IT–TIMI-22 Study
Ray et al. (1) discuss the early and late benefits of 80 mg/day of
atorvastatin in the acute coronary syndrome patients of the
PROVE IT–TIMI-22 (Pravastatin or Atorvastatin Evaluation
and Infection Trial–Thrombolysis In Myocardial Infarction-22),
and they conclude that the early benefit observed in this trial is
likely due to the pleiotropic effects of the statin used.
Conversely, the difference in the triple end-point incidence they
observe after 30 days, as can be seen in Table 1 of their study, is
limited to patients with plasma low density lipoprotein (LDL)
cholesterol levels 125 mg/dl at randomization (hazard ratio
[HR] 0.31; 95% confidence interval [CI] 0.15 to 0.64; p  0.002),
whereas it is completely absent in patients with LDL cholesterol
125 mg/dl at randomization (HR 0.92; 95% CI 0.63 to 1.36; p
 0.7). It is intriguing that a purported nonlipidic effect of a statin
is observed only in patients with elevated LDL cholesterol.
Pleiotropic effects should, conceptually, exert their protective
properties at any lipid level.
Attribution of the early protective action observed in the
PROVE IT–TIMI-22 trial to the pleiotropic effects of the statin
used should be, in our opinion, more cautious. In actuality, a clear
demonstration of the clinical relevance of these effects is still
lacking. A recent meta-regression of published clinical trials
testing different hypolipidemic treatments concludes that choles-
terol reduction is likely to be the major (or unique) determinant of
coronary heart disease and stroke events reduction (2).
Indeed, LDL reduction obtained by a single LDL apheresis
markedly reduces C-reactive protein and ameliorates the endothe-
lial function of coronary arteries (3), suggesting that LDL reduc-
tion, by itself, can rapidly translate into a variety of biochemical or
clinical benefits. Perhaps we should abandon the concept of
“pleiotropic effects of statins” in favor of that of “pleiotropic effects
of cholesterol reduction.”
*Andrea Poli, MD
Arturo Pujia, MD
*University of Milan
Pharmacological Sciences
via Balzaretti, 9
viale Tunisia, 38
Milan
Italy
E-mail: poli.nfi@tin.it
doi:10.1016/j.jacc.2006.05.039
REFERENCES
1. Ray KK, Cannon CP, McCabe CH, et al. Early and late benefits of
high-dose atorvastatin in patients with acute coronary syndromes:
results from the PROVE-IT–TIMI-22 trial. J Am Coll Cardiol
2005;46:1405–10.
2. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of
statins: benefit beyond cholesterol reduction? A meta-regression anal-
ysis. J Am Coll Cardiol 2005;46:1855–62.
3. Igarashi K, Tsuji M, Nishimura M, Horimoto M. Improvement of
endothelium-dependent coronary vasodilation after a single LDL
apheresis in patients with hypercholesterolemia. J Clin Apheresis
2004;19:11–16.
REPLY
We thank Drs. Poli and Pujia for their interest in our report (1). They
suggest that the more significant reduction in clinical events observed
among patients with a high low-density lipoprotein cholesterol
(LDL-C) versus those with a low LDL-C at baseline provides
evidence that the early benefits observed at 30 days are related more to
lipids than any potential pleiotropic effects. Acute coronary syndrome
(ACS) patients have a high early recurrence of adverse events after
ACS. The significant early benefits of intensive statin therapy ob-
served by day 30 in the PROVE IT–TIMI-22 (Pravastatin or
Atorvastatin Evaluation and Infection Therapy–Thrombolysis In
Myocardial Infarction-22) trial seem more striking when compared to
the benefits of intensive LDL-C reduction by ileal bypass in the
POSCH (Program on the Surgical Control of the Hyperlipidemias)
study, which took nearly seven years to translate into clinical benefit
(2). Similarly, in the early statin trials in stable coronary artery disease
(CAD) the benefits of statins were observed after one to two years,
suggesting that in stable patients the benefits of modest reductions in
LDL-C take place over a period of years rather than days. Whereas
we agree that LDL-C reduction itself is associated with reductions in
C-reactive protein (CRP) and endothelial function, we have demon-
strated that, independent of achieved LDL-C and other correlates,
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